Vaxart, Inc. (VXRT)

Market Cap	154.43M +13.5%
Revenue (ttm)	255.61M +439.3%
Net Income	37.10M
EPS	0.16
Shares Out	241.29M
PE Ratio	4.05
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	229,027
Open	0.5400
Previous Close	0.5400
Day's Range	0.5390 - 0.6200
52-Week Range	0.2606 - 0.8449
Beta	1.10
Analysts	Strong Buy
Price Target	3.00 (+428.17%)
Earnings Date	Aug 6, 2026

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Steven Lo
• Employees: 65
• Stock Exchange: OTCMKTS
• Ticker Symbol: VXRT

Analyst Summary

According to 3 analysts, the average rating for VXRT stock is "Strong Buy." The 12-month stock price target is $3.00, which is an increase of 428.17% from the latest price.

Price Target

$3.00

(428.17% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 6, 2026

Data Sources Report a data error